Capping a roller coaster journey, AstraZeneca has steered its lupus drug anifrolumab across the finish line.
Saphnelo, as the antibody will be
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
